Strategic Partnerships CereVasc has established strategic partnerships with prestigious institutions like Tufts Medicine, showcasing credibility and creating avenues for collaborative sales and distribution opportunities.

Breakthrough Device Designation With the FDA granting Breakthrough Device Designation for its eShunt System, CereVasc gains accelerated market access and increased visibility, paving the way for faster adoption and potential sales growth.

Significant Investment Securing a $70 million investment from Bain Capital and others indicates investor confidence in CereVasc's innovative solutions, offering financial stability and resources to further drive sales expansion and market penetration.

Experienced Leadership The appointment of Evan Greif from Bain Capital to CereVasc's Board of Directors brings invaluable industry expertise and network connections, potentially opening doors to new client relationships and business opportunities.

Global Expansion CereVasc's expansion into international markets such as China with the launch of its eShunt System signifies a readiness to tap into new customer bases, indicating a broader sales reach and potential revenue growth.